TCF
NEUTRALTheraCryf Advances Ox-1 Programme with Manufacturing Scale Up
The clinical-stage therapeutics company has initiated the manufacturing scale-up of its lead Ox-1 programme, a key milestone in the development process.
Theracryf
0.2250GBX
0.00%
Market Cap
4.84M
Volume
86.03k
4% of avg
P/E Ratio
-0.00
EPS (TTM)
-0.5
Beta
1.26
Day Range
0.0000p - 0.0000p
52 Week Range
0.0000p0.2250p1.2500p
0.2250p
Upcoming Events
Early 2026
Expected start of SFX-01 study in glioblastoma patients
High Impact Event
Late Q4 2026
End of current cash runway
High Impact Event
TCF
NEUTRALTheraCryf Provides AGM Update on Ox-1 and SFX-01 Programmes
The clinical-stage drug developer updates on the development of its addiction and brain disorder therapies, Ox-1 and SFX-01.
TCF
NEUTRALTheraCryf Plc Announces AGM and Investor Presentation
The healthcare company announces details of its upcoming AGM and an investor presentation following the meeting.
TCF
NEUTRALTheracryf Plc Appoints New Nominated Adviser and Joint Broker
The clinical stage drug development company has appointed a new nominated adviser and joint broker.
TCF
NEUTRALTheraCryf Plc Hosts Ox-1 Investor Presentation
The clinical stage therapeutics company is hosting an investor presentation on its Ox-1 addiction programme.
TCF
NEUTRALTheraCryf Extends Cash Runway to Q4 2026, Focuses on Orexin-1 Antagonist Program
The clinical-stage drug developer has extended its cash runway and sharpened focus on its orexin-1 antagonist program for addiction treatment, while maintaining progress in other areas.
TCF
NEUTRALTheraCryf Plc Announces Full Year Results and Ox-1 Presentation
The clinical-stage therapeutics company announces the release of its full year results and a presentation on its Ox-1 addiction programme.
TCF
NEUTRALTheracryf Plc Announces Change in Shareholding
The healthcare company has announced a transfer of a 19.67% shareholding from Tracarta Limited to its 51% owned subsidiary, Northern Standard Limited.
TCF
NEUTRALTheraCryf Director Increases Stake
The healthcare company has announced a change in one of its director's shareholdings.
TCF
NEUTRALTheracryf Plc Announces Director Dealings
The healthcare company has announced changes to its major shareholdings.